2016 Publications

Nataatmadja M, Cho Y, Johnson DW. Continuous quality improvement initiatives to sustainably reduce peritoneal dialysis-related infections in Australia and New Zealand. Peritoneal Dialysis International, IN PRESS

Davis E, Campbell K, Gobe G, Hawley C, Isbel N, Johnson DW. Association of anthropometric measures with kidney disease progression and mortality: A retrospective cohort study of pre-dialysis chronic kidney disease patients referred to a specialist renal service. BMC Nephrology, IN PRESS

Briskey D, Tucker PS, Johnson DW, Coombes JS. Microbiota and the nitrogen cycle: Implications in the development and progression of CVD and CKD. Nitric Oxide. May 2016.

Lan PG, Clayton PA, Johnson DW, McDonald SP, Borlace M, Sud K, Badve SV, Boudville N. Duration of Haemodialysis following Peritoneal Dialysis cessation in Australia and New Zealand: Proposal for a standardized definition of technique failure. Perit Dial Int. May 2016

Badve SV, Palmer SC, Strippoli GF, Roberts MA, Teixeira-Pinto A, Boudville N, Cass A, Hawley CM, Hiremath SS, Pascoe EM, Perkovic V, Whalley GA, Craig JC, Johnson DW. The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis. Am J Kidney Dis. April 2016.

Young V, Balaam S, Orazio L, Bates A, Badve SV, Johnson DW, Campbell KL. Appetite predicts intake and nutritional status in patients receiving peritoneal dialysis. J Ren Care. June 2016.

Gobe GC, Ng KL, Small DM, Vesey DA, Johnson DW, Samaratunga H, Oliver K, Wood S, Barclay JL, Rajandram R, Li L, Morais C. Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways. Biochem Biophys Res Commun. April 2016.

Nadeau-Fredette AC, Johnson DW, Nesrallah G. Con: Buttonhole cannulation of arteriovenous fistulae. Nephrol Dial Transplant. 31(4):525-8, 2016

Urquhart-Secord R, Craig JC, Hemmelgarn B, Tam-Tham H, Manns B, Howell M, Polkinghorne KR, Kerr PG, Harris DC, Thompson S, Schick-Makaroff K, Wheeler DC, van Biesen W, Winkelmayer WC, Johnson DW, Howard K, Evangelidis N, Tong A. Patient and Caregiver Priorities for Outcomes in Hemodialysis: An International Nominal Group Technique Study. Am J Kidney Dis. March 2016.

Briskey D, Tucker P, Johnson DW, Coombes JS. The role of the gastrointestinal tract and microbiota on uremic toxins and chronic kidney disease development. Clin Exp Nephrol. March 2016.

Zhang L, Hawley CM, Johnson DW. Focus on peritoneal dialysis training: working to decrease peritonitis rates. Nephrol Dial Transplant. February 2016.

Zhang L, Lee G, Liu X, Pascoe EM, Badve SV, Boudville NC, Clayton PA, Hawley CM, Kanellis J, McDonald SP, Peh CA, Polkinghorne KR, Johnson DW. Long-term outcomes of end-stage kidney disease for patients with lupus nephritis. Kidney Int. April 2016.

Fahim MA, Hayen AD, Horvath AR, Dimeski G, Coburn A, Tan KS, Johnson DW, Craig JC, Campbell SB, Hawley CM. Biological variation of high sensitivity cardiac troponin-T in stable dialysis patients: implications for clinical practice. Clin Chem Lab Med. April 2016.

Marshall MR, Polkinghorne KR, Kerr PG, Hawley CM, Agar JW, McDonald SP. Intensive Hemodialysis and Mortality Risk in Australian and New Zealand Populations. Am J Kidney Dis. April 2016.

Cho Y, Büchel J, Steppan S, Passlick-Deetjen J, Hawley CM, Dimeski G, Clarke M, Johnson DW; balANZ Trial Investigators. Longitudinal Trend in Lipid Profile of Incident Peritoneal Dialysis Patients is Not Influenced by the Use of Biocompatible Solutions. Perit Dial Int. 2016

Zhang L, Liu X, Pascoe EM, Badve SV, Boudville NC, Clayton PA, De Zoysa J, Hawley CM, Kanellis J, McDonald SP, Peh CA, Polkinghorne KR, Johnson DW. Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: A multi-centre registry study. Nephrology (Carlton). May 2016

Krishnasamy R, Hawley CM, Stanton T, Howden EJ, Beetham KS, Strand H, Leano R, Haluska BA, Coombes JS, Isbel NM. Association between left ventricular global longitudinal strain, health-related quality of life and functional capacity in chronic kidney disease patients with preserved ejection fraction. Nephrology (Carlton). February 2016

Nadeau-Fredette AC, Chan CT, Cho Y, Hawley CM, Pascoe EM, Clayton PA, Polkinghorne KR, Boudville N, Leblanc M, Johnson DW.  Outcomes of integrated home dialysis care:  a multi-centre, multi-national registry study.  Nephrol Dial Transplant 2015; Jun 4 [Epub ahead of print]

Nadeau-Fredette AC, Johnson DW, Hawley CM, Pascoe EM, Cho Y, Clayton PA, Borlace M, Badve SV, Sud K, Boudville N, McDonald SP.  Centre-specific factors associated with peritonitis risk – a multi-center registry study.  Perit Dial Int 2016; Jan 13 [Epub ahead of press]

Neuen BL, Leather N, Greenwood AM, Gunnarsson R, Cho Y, Mantha ML.  Neutrophil-lymphocyte ratio predicts cardiovascular and all-cause mortality in hemodialysis patients.  Ren Fail 2016; 38(1): 70-6.

Nataatmadja M, Cho Y, Fahim M, Johnson DW.  Recent clinical trials of pharmacologic cardiovascular interventions in patients with chronic kidney disease:  An update.  Rev Recent Clin Trials, 2016; 11(1): 12-32

Mahmood U, Cho Y, Johnson DW. Peritoneal dialysis solutions. In: Ekart R (ed.), Peritoneal dialysis, InTech, Rijeka, Croatia, 2016.

Nataatmadja M, Cho Y, Lloyd J, Johnson DW. Aminoglycoside use in patients with chronic kidney disease. In: Kruger E (ed.), Aminoglycosides: Pharmacology, Clinical Uses and Health Effects, Nova Science, New York, 2016.

Mehrotra R, Devuyst O, Davies SJ, Johnson DW. The current state of peritoneal dialysis. Journal of the American Society of Nephrology (In press; Acceptance date 22 May 2016).

Zhang L, Lee G, Liu X, Pascoe E, Badve SV, Boudville NC, Clayton PA, Hawley CM, Kanellis J, McDonald SP, Peh CA, Polkinghorne KR, Johnson DW. Long term outcomes of end stage kidney disease for patients with lupus nephritis: a multi-center registry study. Kidney International 89:1337-45, 2016.

Palmer SC, Gardner S, Craig JC, Tonelli M, Mavridis D, Johnson DW, French R, Ruospo M, Strippoli GFM. Phosphate binding agents in adults with chronic kidney disease: a network meta-analysis. American Journal of Kidney Diseases (In press; Acceptance date 14 May 2016).

Rossi M, Johnson DW, Morrison M, Pascoe EM, Coombes JS, Forbes JM, Szeto CC, McWhinney BC, Ungerer JPJ, Campbell KL. SYNbiotics Easing Renal failure by improving Gut microbiologY (SYNERGY): a randomised trial. Clinical Journal of the American Society of Nephrology 11(2):223-31, 2016.

Ellis RJ, Small DM, Vesey DA, Johnson DW, Francis R, Vitetta L, Gobe GC, Morais C. Indoxyl sulphate and kidney disease: causes, consequences and interventions. Nephrology 21: 170-7, 2016.

Mudge DW, Webster AC, Johnson DW. Meta-analysis – the case for. Nephrology Dialysis Transplantation 31(6):875-800, 2016.

Mudge DW, Boudville N, Brown F, Clayton P, Duddington M, Holt S, Johnson DW, Jose M, Saweirs W, Sud K, Voss D, Wlaker R. Peritoneal dialysis practice in Australia and New Zealand: a call to sustain the action. Nephrology 2016 Jan 25. doi: 10.1111/nep.12731. [Epub ahead of print].

Chan S, Au K, Francis RS, Mudge DW, Johnson DW, Pillans PI. Phosphate binders in patients with chronic kidney disease. Australian Prescriber (In press; Acceptance date 1 April 2016).

Li PKT, Szeto CC, Piraino B, de Arteaga JD, Fan S, Figuiredo AE, Fish DN, Goffin E, Kim YL, Salzer W, Struijk D, Teitelbaum I, Johnson DW. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Peritoneal Dialysis International (In press; Acceptance date 22 April 2016).

Nadeau-Fredette, Johnson DW. Buttonhole cannulation in haemodialysis – Opponent’s comments. Nephrology Dialysis Transplantation 31:524, 2016.

Mudge DW, Webster AC, Johnson DW. Meta-analysis – rebuttal. Nephrology Dialysis Transplantation 31(6):885-6, 2016.

See E, Hawley CM, Agar J, Johnson DW. Fluid convection, generation and reinfusion in haemodiafiltraton. In: Karkar A (ed.), Advances in Hemodiafiltration, InTech, Rijeka, Croatia, 2016.

Mahmood U, Cho Y, Johnson DW. Peritoneal dialysis solutions. In: Ekart R (ed.), Peritoneal dialysis, InTech, Rijeka, Croatia, 2016.

Chan S, Fahim MA, Macdonald GA, Johnson DW. Treatment of hepatitis B in patients with chronic kidney disease. In: Hepatitis B treatment, Avid Science, Berlin, Germany, 2016.

Nataatmadja M, Cho Y, Lloyd J, Johnson DW. Aminoglycoside use in patients with chronic kidney disease. In: Kruger E (ed.), Aminoglycosides: Pharmacology, Clinical Uses and Health Effects, Nova Science, New York, 2016.

Szeto CC, Li PK, Johnson DW, Bernardini J, Dong J, Figuiredo AE, Ito Y, Kazancioglu R, Moraes T, van Esch S, Brown EA. International Society for Peritoneal Dialysis (ISPD) catheter-related infections recommendations: 2016 update. Peritoneal Dialysis International (In press; Acceptance date 6 June 2016).

Badve SV, Pascoe EM, Burke M, Clayton PA, Campbell SB, Lim WH, McDonald SP, Wong G, Johnson DW. Mammalian target of rapamycin inhibitors and clinical outcomes in adult kidney transplant recipients. Clinical Journal of the American Society of Nephrology (In press; Acceptance date 7 June 2016).

Cho Y, Büchel J, Steppan S, Passlick-Deetjen J, Hawley CM, Dimeski G, Clarke M, Johnson DW. Longitudinal trend in lipid profile of incident peritoneal dialysis patients is not influenced by the use of biocompatible solutions. Peritoneal Dialysis International 36(2):146-153, 2016.

Perl J, Davies DJ, Lambie M, Pisoni RL, McCullough KP, Johnson DW, Sloand JA, Prichard S,  Kawanishi H, Tentori F, Robinson BM. The Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS):  Unifying Efforts to Inform Practice and Improve Global Outcomes in Peritoneal Dialysis. Peritoneal Dialysis International 36(3):297-307, 2016.

Young V, Balaam S, Orazio L, Bates A, Badve SV, Johnson DW, Campbell KL. Appetite predicts intake and nutritional status in peritoneal dialysis patients. Journal of Renal Care 42(2):123-31, 2016.

Liuzzi AR, Kift-Morgan A, Anton ML, Friberg IM, Zhang J, Brook AC, Roberts GW, Donovan KL, Colmont CS, Toleman MA, Bowen T, Johnson DW, Topley N, Moser B, Fraser DJ, Eberl M. Unconventional human T-cells accumulate at the site of infection in response to microbial ligands and induce local tissue remodeling. The Journal of Immunology (In press; Acceptance date 14 July 2016).

“The Global Kidney Health Atlas,” International Society of Nephrology Global Kidney Health Summit, Vancouver, Canada, 26-29 July, 2016.

“Why move from standard solutions to ultralow GDP solutions?”, Province-wide rounds, UBC Division of Nephrology, Vancouver, Canada, 29 July 2016.

Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, Maggo J, Gray V, De Berardis G, Ruospo M, Natale P, Saglimbene V, Badve S, Cho Y, Nadeau-Fredette AC, Burke M, Faruque L, Lloyd A, Ahmad N, Liu Y, Tiv S, Wiebe N, Strippoli GFM. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 316(3):313-24, 2016.

Johnson DW. Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes. BMJ Evidence-Based Medicine (In press; Acceptance date 30 July 2016).

Zhang L, Coombes J, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW, on behalf of the HERO Study Collaborative Group. The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis stimulating agent hyporesponsiveness: substudy of the HERO trial. Redox Reports 2015 Jun 17 [Epub ahead of print].

Badve SV, Palmer SC, Hawley CM, Pascoe EM, Strippoli GFM, Johnson DW. Glomerular Filtration Rate Decline as a Surrogate Endpoint in Kidney Disease Progression Trials Review – Clinical science and outcome research in nephrology. Nephrology Dialysis Transplantation 2015 Jul 11. pii: gfv269. [Epub ahead of print].

Nadeau-Fredette AC, Hawley C, Pascoe E, Chan CT, Leblanc  M, Clayton PA, Polkinghorne KR, Boudville N, Johnson DW. Predictors of transfer to home hemodialysis after peritoneal dialysis completion. Peritoneal Dialysis International 2015 Nov 2. pii: pdi.2015.00121. [Epub ahead of print].

Nadeau-Fredette AC, Johnson DW, Hawley CM, Pascoe EM, Cho Y, Clayton PA, Borlace M, Badve SV, Sud K, Boudville N, McDonald SP. Centre-specific factors associated with peritonitis risk – a multi-center registry analysis. Peritoneal Dialysis International 2016 Jan 13. pii: pdi.2015.00146. [Epub ahead of print].

Palmer SC, Ruospo M, Wong G, Craig JC, Petruzzi M, De Benedittis M, Ford P, Johnson DW, Tonelli M, Natale P, Saglimbene V, Pellegrini F, Celia E, Gelfman R, Leal MR, Torok M, Stroumza P, Frantzen L, Bednarek-Skublewska A, Dulawa J, del Castillo D, Bernat AG, Hegbrant J, Wollheim C, Schon S, Gargano L, Bots CP, Strippoli GFM. Patterns of oral disease in adults with chronic kidney disease treated with hemodialysis. Nephrology Dialysis Transplantation 2015 Dec 29. pii: gfv413. [Epub ahead of print].

Lan PG, Clayton PA, Johnson DW, McDonald SP, Borlace M, Badve SV, Sud K, Boudville N. Duration of hemodialysis following peritoneal dialysis cessation in Australia and New Zealand: Proposal for a standardized definition of technique failure. Peritoneal Dialysis International 2016 May 4. pii: pdi.2015.00218. [Epub ahead of print].

Badve S, Palmer SC, Strippoli GFM, Roberts MA, Teixera-Pinto A, Boudville N, Cass A, Hawley CM, Hiremath SS, Pascoe EM, Perkovic V, Whalley GA, Craig JC, Johnson DW. The Validity of Left Ventricular Mass as a Surrogate Endpoint for All-cause and Cardiovascular Mortality Outcomes in People with Chronic Kidney Disease: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases. 2016 Apr 30. pii: S0272-6386(16)30024-5. doi: 10.1053/j.ajkd.2016.03.418. [Epub ahead of print].

Gobe GC, Ng KL, Small DM, Vesey DA, Johnson DW, Samaratunga H, Oliver K, Wood S, Barclay JL, Rajandram R, Li L, Morais C. Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways. Biochemical and Biophysical Research Communications 473(1):47-53, 2016.

Boonprasert K, Vesey DA, Gobe GC, Moore MR, Ruenweerayut R, Johnson DW, Na-Bangchang K, Satarug S. The stress response of human proximal tubules cells to cadmium involves up-regulation of haemoxygenase-1 and metallothionein but not cytochrome P450 enzymes. Toxicology Letters. 249:5-14, 2016.

Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS for the TEMPO 3:4 Trial Investigators. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial. Clin J Am Soc Nephrol. 11(5):803-11, 2016.

Urquhart-Secord R, Craig JC, Hemmelgarn B, Tam-Tham H, Manns B, Howell M, Polkinghorne KR, Kerr PG, Harris DC, Thompson S, Schick-Makaroff K, Wheeler DC, Van Biesen W, Winkelmayer WC, Johnson DW, Howard K, Evangelidis N, Tong A. Patient and caregiver priorities for outcomes in hemodialysis: an international nominal group technique study. American Journal of Kidney Disease 68(3):444-454, 2016.

Nataatmadja M, Cho Y, Johnson DW. Evidence for biocompatible peritoneal dialysis solutions. Contributions to Nephrology (In press; Acceptance date 13 September 2016).

Li P, Chow KM, Johnson DW, Lameire N, Mehrotra R, Naicker S, Pecoits-Filho R, Yu X, van de Luijtgaarden M, Jager K. Changes in the worldwide epidemiology of peritoneal dialysis. Nature Reviews Nephrology (In press; Acceptance date 13 September 2016).

Krishnasamy R, Hawley CM, Johnson DW. An update on bone imaging and markers in chronic kidney disease. Expert Review of Endocrinology & Metabolism (In press; Acceptance date 19 September 2016).

See EJ, Cho Y, Hawley CM, Jaffrey LR, Johnson DW. Early and late patient outcomes in urgent start peritoneal dialysis. Peritoneal Dialysis International (In press; Acceptance date 20 September 2016).

Krishnasamy R, Hawley CM, Johnson DW. An update on bone imaging and markers in chronic kidney disease. Expert Review of Endocrinology & Metabolism (In press; Acceptance date 19 September 2016).

Nadeau-Fredette AC, Johnson DW, Hawley CM, Pascoe EM, Cho Y, Clayton PA, Borlace M, Badve SV, Sud K, Boudville N, McDonald SP. Centre-specific factors associated with peritonitis risk – a multi-center registry analysis. Peritoneal Dialysis International 36(5):509-18, 2016

Li PKT, Szeto CC, Piraino B, de Arteaga JD, Fan S, Figuiredo AE, Fish DN, Goffin E, Kim YL, Salzer W, Struijk D, Teitelbaum I, Johnson DW. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Peritoneal Dialysis International 36(5):481-508, 2016

Htay H, Cho Y, Pascoe EM, Darssan D, Hawley CM, Johnson DW on behalf of the balANZ Trial Investigators. Predictors of residual renal function decline in peritoneal dialysis patients: the balANZ trial. Peritoneal Dialysis International (In press; Acceptance date 2 October 2016).

Zhang L, Badve SB,Pascoe EM, Beller E, Cass A, Clark C, de Zoysa J, Isbel NM, Liu X, McTaggart S, Morrish AT, Playford EG, Scaria A, Snelling P, Vergara LA, Hawley CM, Johnson DW. Representativeness of HONEYPOT trial participants to Australasian PD patients. Peritoneal Dialysis International (In press; Acceptance date 2 October 2016).

Chan S, Campbell SB, Clayton PA, Mudge DW, Cho Y, Hawley CM, Johnson DW, Francis R. Temporal changes in deceased kidney donor characteristics in Australia. Transplantation Direct 2:e112, 2016.

Htay H, Johnson DW, Oei EL, Wu SY, Kong LP, Kwok CYH, Foo MWY, Cho JCJ. Comparison of topical chlorhexidine and mupirocin for the prevention of exit site infection in incident peritoneal dialysis patients. Peritoneal Dialysis International (In press; Acceptance date 7 November 2016).

Lan PG, Clayton PA, Johnson DW, McDonald SP, Borlace M, Badve SV, Sud K, Boudville N. Duration of hemodialysis following peritoneal dialysis cessation in Australia and New Zealand: Proposal for a standardized definition of technique failure. Peritoneal Dialysis International 36(6): 623-30, 2016.

Chan S, Campbell SB, Clayton PA, Mudge DW, Cho Y, Hawley CM, Johnson DW, Francis R. Temporal changes in deceased kidney donor characteristics in Australia. Transplantation Direct (In press; Acceptance date 18 August 2016).

Evangelidis N, Tong A, Manns B, Hemmelgarn B, Wheeler DC, Tugwell P, Crowe S, Harris T, Van Biesen W, Winkelmayer WC, Sautenet B, O’Donoghue D, Tam-Tham H, Youssouf S, Mandayam S, Ju A, Hawley C, Pollock C, Harris DC, Johnson DW, Rifkin DE, Tentori F, Agar J, Polkinghorne KR, Gallagher M, Kerr PG, McDonald SP, Howard K, Craig JC. Developing a set of core outcomes for trials in hemodialysis: an international Delphi survey. American Journal of Kidney Disease [Accepted 29th November 2016]

Wing SN, Kelly J, Johnson DW, Campbell KL. Dietary patterns and clinical outcomes in chronic kidney disease: The CKD.QLD nutrition study. Journal of Renal Nutrition (In press; Acceptance date 20 October 2016).

Irish AB, Viecelli AK, Hawley CM, Hooi LS, Pascoe EM, Paul-Brent PA, Badve SV, Mori TA, Cass A, Kerr PG, Voss D, Ong LM, Polkinghorne KR, for the Omega-3 Fatty Acids (Fish Oils) and Aspirin in Vascular Access Outcomes in Renal Disease (FAVOURED) Study Collaborative Group. The omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study – a randomized placebo-controlled trial. JAMA Internal Medicine (In press; Acceptance date accepted Thursday, 20 October 2016).

Nataatmadja M, Cho Y, Johnson DW. Evidence for biocompatible peritoneal dialysis solutions. Contributions to Nephrology 189:91-101, 2017

Szeto CC, Johnson DW. Low GDP solution and glucose sparing strategies for peritoneal dialysis. Seminars in Dialysis (In press; Acceptance date 2 November 2016).

Evangelidis N, Tong A, Manns B, Hemmelgarn B, Wheeler DC, Tugwell P, Crowe S, Harris T, Van Biesen W, Winkelmayer WC, Sautenet B, O’Donaghue D, Tam-Tham H, Youssouf S, Mandayam S, Ju A, Hawley C, Pollock C, Harris DC, Johnson DW, Rifkin D, Tentori F, Agar J, Polkinghorne KP, Gallagher M, Kerr PG, McDonald SP, Howard K, Howell M, Craig JC for the Standardized Outcomes in Nephrology – Hemodialysis (SONG-HD) initiative. Developing a set of core outcomes for trials in hemodialysis: An international Delphi survey. American Journal of Kidney Disease (In press Acceptance date 29 November 2016).

Evangelidis N, Craig JC, Tong A; on behalf of the SONG Executive Committee and Investigators. Standardised outcomes in nephrology – haemodialysis (SONG-HD): using the Delphi method to gain consensus on core outcomes for haemodialysis trials. Journal of Renal Care. 2015 Dec;41(4):211-2

Tong A, Manns B, Hemmelgarn B, Wheeler DC, Evangelidis N, Tugwell P, Crowe S, Van Biesen W, Winkelmayer WC, O’Donoghue D, Tam-Tham H, Shen J, Pinter J, Larkins N, Youssouf S, Mandayam S, Ju A, Craig JC, on behalf of the SONG-HD Investigators. Establishing core outcome domains in hemodialysis: report of the Standardised Outcomes in Nephrology – Hemodialysis (SONG-HD) consensus workshops. American Journal of Kidney Disease 2016 August 3rd 2016 (online first) doi: 10.1053/j.ajkd.2016.05.022.

Viecelli  Andrea, Pascoe  Elaine, Polkinghorne  Kevan, Hawley  Carmel, Paul-Brent  Peta-Anne, Badve  Sunil, Cass  Alan, Heritier  Stephane, Kerr  Peter, Mori  Trevor, Robertson  Amanda, Seong  Hooi, Irish  Ashley, on behalf of the FAVOURED study team. The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. BMC Nephrology 2015, 16:89  doi:10.1186/s12882-015-0089-2. http://www.biomedcentral.com/1471-2369/16/89

Palmer SC, Gardner S, Craig JC, Tonelli M, Mavridis D, Johnson DW, French R, Ruospo M, Strippoli GFM. Phosphate binding agents in adults with chronic kidney disease: a network meta-analysis. American Journal of Kidney Diseases 68(5):691-702, 2016.

Davis E, Campbell KL, Gobe G, Hawley CM, Isbel N, Johnson DW. Association of anthropometric measures with kidney disease progression and mortality: A retrospective cohort study of pre-dialysis chronic kidney disease patients referred to a specialist renal service. BMC Nephrology 17(1):74, 2016

Liuzzi AR, Kift-Morgan A, Anton ML, Friberg IM, Zhang J, Brook AC, Roberts GW, Donovan KL, Colmont CS, Toleman MA, Bowen T, Johnson DW, Topley N, Moser B, Fraser DJ, Eberl M. Unconventional human T-cells accumulate at the site of infection in response to microbial ligands and induce local tissue remodeling. The Journal of Immunology 197(6):2195-207, 2016

Badve SV, Palmer SC, Halwy CM, Pascoe EM, Strippoli GFM, Johnson DW. Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials. Nephrology Dialysis Transplantation 31(9):1425-36, 2016

Briskey D, Tucker P, Johnson DW, Coombes JS. : Microbiota and the nitrogen cycle: Implications in the development and progression of cardiovascular disease and chronic kidney disease. Nitric Oxide 57:64-70, 2016.

Nataatmadja M, Cho Y, Johnson DW. Continuous quality improvement initiatives to sustainably reduce peritoneal dialysis-related infections in Australia and New Zealand. Peritoneal Dialysis International 36(5):472-7, 2016

Mehrotra R, Devuyst O, Davies SJ, Johnson DW. The current state of peritoneal dialysis. Journal of the American Society of Nephrology 27(11):3238-3252, 2016

Shen K, Johnson DW, Gobe GC. The role of cyclic GMP and its signaling pathways in kidney disease. American Journal of Physiology 311(4):F671-F681, 2016

Johnson DW. Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes. BMJ Evidence-Based Medicine 21(5):178, 2016

Palmer SC, Tunnicliffe DJ, Mavridis D, Tonelli M, Johnson DW, Craig JC, Tong A, Strippoli GFM. Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: Network meta-analysis. American Journal of Kidney Diseases (In press; Acceptance date 7 December 2016).

Small D, Weston K, Howden E, Briskey D, Johnson DW, Isbel NM, Gobe GC, Coombes J. Effects of exercise and lifestyle intervention on oxidative stress in chronic kidney disease. Redox Report (In press; Acceptance date 19 December 2016).

Mahmood U, Johnson DW, Fahim MA. Cardiac biomarkers in dialysis. AIMS Genetics (In press; Acceptance date 19 December 2016).

Chan S, Burke MT, Johnson DW, Francis RS, Mudge DW. Tacrolimus toxicity due to biliary obstruction in a combined liver and kidney transplant recipient. Case Reports in Transplantation (In press; Acceptance date 22 December 2016).

Xu R, Yang Z, Qu Z, Wang H, Tian X, Johnson DW, Dong J. Comparison of intraperitoneal (IP) vancomycin plus either oral moxifloxacin or IP ceftazidime for the treatment of peritoneal dialysis-related peritonitis: a randomized controlled pilot study. American Journal of Kidney Diseases (In press; Acceptance date 23 December 2016).

AKTN Trial-related

 HONEYPOT

  • Zhang, L, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, deZoysa J, Isbel NM, McTaggart S, Morrish AT, Playford EG, Scaria A, Snelling P, Vergara LA, Hawley CM, Johnson DW, HONEYPOT Study Collaborative Group. The effect of exit site antibacterial honey versus nasal mupirocin prophylaxis on the microbiology and outcomes of peritoneal dialysis-associated peritonitis and exist site infections: a sub-study of the HONEYPOT trial. Peritoneal Dialysis International, doi:3747/pdi.2014.00206. IN PRESS.
  • Zhang L, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, deZoysa J, Isbel NM, Xusheng Liu, McTaggart S, Morrish AT, Playford EG, Scaria A, Snelling P, Vergara LA, Hawley CM, Johnson DW and HONEYPOT Study Collaborative Group. Representativeness of HONEYPOT trial participants to Australasian PD patients. Peritoneal Dialysis International (In press; Acceptance date 2 October 2016).

 

HERO

  • Zhang L, Coombes J, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogas E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW, HERO Study Collaborative Group. The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis stimulating agent hyporesponsiveness: substudy of the HERO trial. Redox Report, Jun 2015 [Epub ahead of print]
  • Gummer J, Trengove R, Pascoe EM, Badve SV, Cass A, Clarke P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Carmel Hawley CM, Johnson DW, Olynk JK, Ferrari P, HERO Study Collaborative Group. Association between Serum Hepcidin-25 and Primary Resistance to Erythropoiesis Stimulating Agents in Chronic Kidney Disease: A Secondary Analysis of the HERO Trial. Nephrology, Nephrology (Carlton). 2016 May 12. doi: 10.1111/nep.12815.

 

BLOCADE

  • Matthew A Roberts, Helen L Pilmore, Francesco L Ierino, Sunil V Badve, Alan Cass, Amit X Garg, Carmel M Hawley, Nicole M Isbel, Henry Krum, Elaine M Pascoe, Anish Scaria, Andrew M Tonkin, Liza A Vergara*, Vlado Perkovic, for the BLOCADE Study Collaborative Group. The Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study. Am J Kidney Dis. 2016 67(6):902-911.

 

FAVOURED

  • Viecelli AK, Pascoe EM, Polkinghorne KR, Hawley CM, Paul-Brent PA, Badve SV, Cass A, Johnson DW, Kerr PG, Mori TA, Scaria A, Hooi SL, Ong ML, Irish AB; FAVOURED Study Team. Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology (Carlton). March 2016.

 

PDOPPS

  • Jeffrey Perl, Simon J. Davies, Mark Lambie, Ronald L. Pisoni, Keith McCullough, David W. Johnson, James A. Sloand, Sarah Prichard, Hideki Kawanishi, Francesca Tentori, and Bruce M. Robinson. The Peritoneal Dialysis outcomes and practice patterns study (PDOPPS): Unifying efforts to inform practice and improve glocal outcomes in peritoneal dialysis.  Peritoneal Dialysis International, in press.  DOI: 10.3747/pdi.2014.00288
  •  Annie-Claire Nadeau-Fredette, Carmel Hawley, Elaine Pascoe, Christopher T. Chan, Martine Leblanc, Philip A. Clayton, Kevan R. Polkinghorne, Neil Boudville, and David W. Johnson. Predictors of Transfer to Home Hemodialysis after Peritoneal Dialysis Completion. Peritoneal Dialysis International, in press.  DOE: 10.3747/pdi.2015.00121

 

 

 David Johnson’s Invited talks:

 “Building economical and sustainable models of nephrology care in Fiji and the Pacific,” 2nd Fiji Nephrology Symposium, 28 September – 1 October 2016 (Opening plenary)

“Travel-associated issues in patients with advanced kidney disease,” 2nd Fiji Nephrology Symposium, 28 September – 1 October 2016 (Keynote lecture)

“Building research in Fiji – what are the building blocks?” 2nd Fiji Nephrology Symposium, 28 September – 1 October 2016 (Keynote lecture)

 President-Elect, International Society for Peritoneal Dialysis 2016-2018

Editorial Board Member, Clinical Journal of the American Society of Nephrology, 2016-2018

 “What can we learn in peritoneal dialysis from the DOPPS approach?” American Society of Nephrology Kidney Week, Chicago, USA, 15-20 November 2016.

“Peritoneal dialysis-related peritonitis: building the bridge between evidence and practice,” American Society of Nephrology Kidney Week, Chicago, USA, 15-20 November 2016.

“The Global Kidney Health Atlas project,” American Society of Nephrology Kidney Week, Chicago, USA, 15-20 November 2016.

“Peritoneal Dialysis-related peritonitis: what evidence do we need?” Asia-Pacific Congress of Nephrology, Perth, 17-21 September 2016.